Investigational Asthma Treatment Cuts Exacerbation Rates in Half – Pharmacy Times (registration)

Investigational Asthma Treatment Cuts Exacerbation Rates in Half
Pharmacy Times (registration)
The study compared the anti-interleukin-5 (IL-5) monoclonal antibody, reslizumab, with placebo in 953 patients with both asthma and elevated blood eosinophil levels. The research team found that patients treated with reslizumab in the first study

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.